

Javier Saez

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1187458/publications.pdf>

Version: 2024-02-01

86
papers

3,002
citations

212478

28
h-index

206121

51
g-index

88
all docs

88
docs citations

88
times ranked

4232
citing authors

#	ARTICLE	IF	CITATIONS
1	Altered Balance of Reelin Proteolytic Fragments in the Cerebrospinal Fluid of Alzheimer's Disease Patients. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7522.	1.8	3
2	Tau phosphorylation by glycogen synthase kinase 3 β modulates enzyme acetylcholinesterase expression. <i>Journal of Neurochemistry</i> , 2021, 157, 2091-2105.	2.1	17
3	Plasma ACE2 species are differentially altered in COVID-19 patients. <i>FASEB Journal</i> , 2021, 35, e21745.	0.2	18
4	The apolipoprotein receptor LRP3 compromises APP levels. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 181.	3.0	9
5	Amyloid precursor protein glycosylation is altered in the brain of patients with Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 96.	3.0	24
6	β -Secretase nonsense mutation (ADAM10 Tyr167*) in familial Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 139.	3.0	13
7	Elevated Plasma Reelin Levels in Children With Autism. <i>Frontiers in Psychiatry</i> , 2020, 11, 242.	1.3	8
8	Characterization of Cerebrospinal Fluid BACE1 Species. <i>Molecular Neurobiology</i> , 2019, 56, 8603-8616.	1.9	4
9	Pre-analytical stability of novel cerebrospinal fluid biomarkers. <i>Clinica Chimica Acta</i> , 2019, 497, 204-211.	0.5	9
10	Measurement of CSF β -synuclein improves early differential diagnosis of mild cognitive impairment due to Alzheimer's disease. <i>Journal of Neurochemistry</i> , 2019, 150, 218-230.	2.1	12
11	CSF-ApoER2 fragments as a read-out of reelin signaling: Distinct patterns in sporadic and autosomal-dominant Alzheimer disease. <i>Clinica Chimica Acta</i> , 2019, 490, 6-11.	0.5	3
12	Decreased circulating ErbB4 ectodomain fragments as a read-out of impaired signaling function in amyotrophic lateral sclerosis. <i>Neurobiology of Disease</i> , 2019, 124, 428-438.	2.1	11
13	Inhibition of β -Secretase Leads to an Increase in Presenilin-1. <i>Molecular Neurobiology</i> , 2018, 55, 5047-5058.	1.9	19
14	Decreased generation of C-terminal fragments of ApoER2 and increased reelin expression in Alzheimer's disease. <i>FASEB Journal</i> , 2018, 32, 3536-3546.	0.2	23
15	Levels of ADAM10 are reduced in Alzheimer's disease CSF. <i>Journal of Neuroinflammation</i> , 2018, 15, 213.	3.1	39
16	HNK-1 Carrier Glycoproteins Are Decreased in the Alzheimer's Disease Brain. <i>Molecular Neurobiology</i> , 2017, 54, 188-199.	1.9	13
17	C-terminal fragments of the amyloid precursor protein in cerebrospinal fluid as potential biomarkers for Alzheimer disease. <i>Scientific Reports</i> , 2017, 7, 2477.	1.6	28
18	Alterations in the Balance of Amyloid- β Protein Precursor Species in the Cerebrospinal Fluid of Alzheimer's Disease Patients. <i>Journal of Alzheimer's Disease</i> , 2017, 57, 1281-1291.	1.2	4

#	ARTICLE	IF	CITATIONS
19	Neuromuscular Junction Impairment in Amyotrophic Lateral Sclerosis: Reassessing the Role of Acetylcholinesterase. <i>Frontiers in Molecular Neuroscience</i> , 2016, 9, 160.	1.4	49
20	The β -amyloid peptide compromises Reelin signaling in Alzheimer's disease. <i>Scientific Reports</i> , 2016, 6, 31646.	1.6	44
21	Reelin in Alzheimer's Disease, Increased Levels but Impaired Signaling: When More is Less. <i>Journal of Alzheimer's Disease</i> , 2016, 52, 403-416.	1.2	30
22	Cerebrospinal fluid Presenilin-1 increases at asymptomatic stage in genetically determined Alzheimer's disease. <i>Molecular Neurodegeneration</i> , 2016, 11, 66.	4.4	9
23	Increased Expression of Readthrough Acetylcholinesterase Variants in the Brains of Alzheimer's Disease Patients. <i>Journal of Alzheimer's Disease</i> , 2016, 53, 831-841.	1.2	26
24	Transmembrane Amyloid-Related Proteins in CSF as Potential Biomarkers for Alzheimer's Disease. <i>Frontiers in Neurology</i> , 2015, 6, 125.	1.1	15
25	Heteromers of amyloid precursor protein in cerebrospinal fluid. <i>Molecular Neurodegeneration</i> , 2015, 10, 2.	4.4	22
26	Validation of a quantitative cerebrospinal fluid alpha-synuclein assay in a European-wide interlaboratory study. <i>Neurobiology of Aging</i> , 2015, 36, 2587-2596.	1.5	30
27	Quantification of the Transcripts Encoding Different Forms of AChE in Various Cell Types: Real-Time PCR Coupled with Standards in Revealing the Copy Number. <i>Journal of Molecular Neuroscience</i> , 2014, 53, 461-468.	1.1	9
28	Acetylcholinesterase Protein Level Is Preserved in the Alzheimer's Brain. <i>Journal of Molecular Neuroscience</i> , 2014, 53, 446-453.	1.1	20
29	Acetylcholinesterase Modulates Presenilin-1 Levels and β -Secretase Activity. <i>Journal of Alzheimer's Disease</i> , 2014, 41, 911-924.	1.2	22
30	ApoER2 processing by presenilin-1 modulates reelin expression. <i>FASEB Journal</i> , 2014, 28, 1543-1554.	0.2	29
31	Presenilin-1 influences processing of the acetylcholinesterase membrane anchor PRiMA. <i>Neurobiology of Aging</i> , 2014, 35, 1526-1536.	1.5	9
32	P2-115: CEREBROSPINAL FLUID PRESENILIN-1 COMPLEXES: A POTENTIAL BIOMARKER FOR ALZHEIMER'S DISEASE. , 2014, 10, P513-P513.		0
33	P3-037: THE B-AMYLOID PEPTIDE COMPROMISES REELIN SIGNALING IN ALZHEIMER'S DISEASE. , 2014, 10, P641-P641.		0
34	CSF Presenilin-1 complexes are increased in Alzheimer's disease. <i>Acta Neuropathologica Communications</i> , 2013, 1, 46.	2.4	22
35	Beta-Amyloid Impairs Reelin Signaling. <i>PLoS ONE</i> , 2013, 8, e72297.	1.1	40
36	Identification of a 31-bp Deletion in the RELN Gene Causing Lissencephaly with Cerebellar Hypoplasia in Sheep. <i>PLoS ONE</i> , 2013, 8, e81072.	1.1	12

#	ARTICLE	IF	CITATIONS
37	Altered expression of brain acetylcholinesterase in FTDP-17 human tau transgenic mice. <i>Neurobiology of Aging</i> , 2012, 33, 624.e23-624.e34.	1.5	24
38	Changes in acetylcholinesterase expression are associated with altered presenilin-1 levels. <i>Neurobiology of Aging</i> , 2012, 33, 627.e27-627.e37.	1.5	23
39	Recommendations to standardize preanalytical confounding factors in Alzheimer's and Parkinson's disease cerebrospinal fluid biomarkers: an update. <i>Biomarkers in Medicine</i> , 2012, 6, 419-430.	0.6	280
40	Readthrough Acetylcholinesterase Is Increased in Human Liver Cirrhosis. <i>PLoS ONE</i> , 2012, 7, e44598.	1.1	25
41	Revisiting the role of acetylcholinesterase in Alzheimer's disease: cross-talk with P-tau and β -amyloid. <i>Frontiers in Molecular Neuroscience</i> , 2011, 4, 22.	1.4	208
42	β -amyloid controls altered Reelin expression and processing in Alzheimer's disease. <i>Neurobiology of Disease</i> , 2010, 37, 682-691.	2.1	53
43	Altered Levels of Acetylcholinesterase in Alzheimer Plasma. <i>PLoS ONE</i> , 2010, 5, e8701.	1.1	93
44	Wheat germ agglutinin-binding glycoproteins are decreased in Alzheimer's disease cerebrospinal fluid. <i>Journal of Neurochemistry</i> , 2008, 79, 1022-1026.	2.1	39
45	Association between acetylcholinesterase and β -amyloid peptide in Alzheimer's cerebrospinal fluid. <i>Chemico-Biological Interactions</i> , 2008, 175, 209-215.	1.7	25
46	Reelin is overexpressed in the liver and plasma of bile duct ligated rats and its levels and glycosylation are altered in plasma of humans with cirrhosis. <i>International Journal of Biochemistry and Cell Biology</i> , 2008, 40, 766-775.	1.2	27
47	Presenilin 1 Interacts with Acetylcholinesterase and Alters Its Enzymatic Activity and Glycosylation. <i>Molecular and Cellular Biology</i> , 2008, 28, 2908-2919.	1.1	26
48	Brain cholinergic impairment in liver failure. <i>Brain</i> , 2008, 131, 2946-2956.	3.7	88
49	Alzheimer's Disease and Reelin. , 2008, , 401-409.		1
50	Glutamate-induced activation of nitric oxide synthase is impaired in cerebral cortex in rats with chronic liver failure. <i>Journal of Neurochemistry</i> , 2007, 102, 51-64.	2.1	35
51	Cerebrospinal fluid acetylcholinesterase changes after treatment with donepezil in patients with Alzheimer's disease. <i>Journal of Neurochemistry</i> , 2007, 101, 1701-1711.	2.1	28
52	Altered glycosylation of acetylcholinesterase in Creutzfeldt-Jakob disease. <i>Journal of Neurochemistry</i> , 2006, 96, 97-104.	2.1	34
53	Altered Glycosylation of Acetylcholinesterase in the Creutzfeldt-Jakob Cerebrospinal Fluid. <i>Journal of Molecular Neuroscience</i> , 2006, 30, 65-66.	1.1	14
54	Changes in liver and plasma acetylcholinesterase in rats with cirrhosis induced by bile duct ligation. <i>Hepatology</i> , 2006, 43, 444-453.	3.6	38

#	ARTICLE	IF	CITATIONS
55	Brain edema and inflammatory activation in bile duct ligated rats with diet-induced hyperammonemia: A model of hepatic encephalopathy in cirrhosis. <i>Hepatology</i> , 2006, 43, 1257-1266.	3.6	147
56	Nogo-A Expression in the Human Hippocampus in Normal Aging and in Alzheimer Disease. <i>Journal of Neuropathology and Experimental Neurology</i> , 2006, 65, 433-444.	0.9	62
57	Reelin expression and glycosylation patterns are altered in Alzheimer's disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 5573-5578.	3.3	196
58	Intraperitoneal administration of 340kDa human plasma butyrylcholinesterase increases the level of the enzyme in the cerebrospinal fluid of rats. <i>Neuroscience Letters</i> , 2005, 383, 93-98.	1.0	4
59	Bile duct ligation plus hyperammonemia in rats reproduces the alterations in the modulation of soluble guanylate cyclase by nitric oxide in brain of cirrhotic patients. <i>Neuroscience</i> , 2005, 130, 435-443.	1.1	22
60	P3-384 Decreased level and altered glycosylation of acetylcholinesterase in creutzfeld-jakob lumbar cerebrospinal fluid. <i>Neurobiology of Aging</i> , 2004, 25, S464-S465.	1.5	0
61	Acetylcholinesterase is increased in mouse neuronal and astrocyte cultures after treatment with β -amyloid peptides. <i>Brain Research</i> , 2003, 965, 283-286.	1.1	25
62	Altered levels of cerebrospinal fluid reelin in frontotemporal dementia and Alzheimer's disease. <i>Journal of Neuroscience Research</i> , 2003, 72, 132-136.	1.3	69
63	Glycosylation of acetylcholinesterase and butyrylcholinesterase changes as a function of the duration of Alzheimer's disease. <i>Journal of Neuroscience Research</i> , 2003, 72, 520-526.	1.3	55
64	Acetylcholinesterase level and molecular isoforms are altered in brain of Reelin Orleans mutant mice. <i>Journal of Neurochemistry</i> , 2003, 87, 773-779.	2.1	5
65	Acetylcholinesterase activation in organotypic rat hippocampal slice cultures deprived of oxygen and glucose. <i>Neuroscience Letters</i> , 2003, 348, 123-125.	1.0	13
66	Acetylcholinesterase activity and molecular isoform distribution are altered after focal cerebral ischemia. <i>Molecular Brain Research</i> , 2003, 117, 240-244.	2.5	15
67	Changes in molecular isoform distribution of acetylcholinesterase in rat cortex and cerebrospinal fluid after intracerebroventricular administration of amyloid β -peptide. <i>Neuroscience Letters</i> , 2002, 325, 199-202.	1.0	31
68	Altered glycosylation of acetylcholinesterase in APP (SW) Tg2576 transgenic mice occurs prior to amyloid plaque deposition. <i>Journal of Neurochemistry</i> , 2002, 81, 441-448.	2.1	41
69	Identification of hybrid cholinesterase forms consisting of acetyl- and butyrylcholinesterase subunits in human glioma. <i>Neuroscience</i> , 2001, 107, 199-208.	1.1	14
70	Acetylcholinesterase and butyrylcholinesterase glycoforms are biomarkers of Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , 2001, 3, 323-328.	1.2	13
71	Molecular Isoform Distribution and Glycosylation of Acetylcholinesterase Are Altered in Brain and Cerebrospinal Fluid of Patients with Alzheimer's Disease. <i>Journal of Neurochemistry</i> , 2001, 72, 1600-1608.	2.1	99
72	Altered glycosylation of cerebrospinal fluid butyrylcholinesterase in alzheimer's disease. <i>Brain Research</i> , 2001, 889, 247-250.	1.1	17

#	ARTICLE	IF	CITATIONS
73	An unusually glycosylated form of acetylcholinesterase is a CSF biomarker for Alzheimer's disease. <i>Acta Neurologica Scandinavica</i> , 2000, 102, 49-52.	1.0	19
74	Altered glycosylation of acetylcholinesterase in lumbar cerebrospinal fluid of patients with Alzheimer's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2000, 69, 664-667.	0.9	36
75	Caspase-3 activation by β -amyloid and prion protein peptides is independent from their neurotoxic effect. <i>Neuroscience Letters</i> , 2000, 293, 207-210.	1.0	31
76	Inhibition of neurite outgrowth from chick sympathetic neurons by cholinesterase inhibitors is not mediated by binding to cholinesterases. <i>Neuroscience Letters</i> , 1999, 266, 77-80.	1.0	7
77	Characterization of molecular forms of acetyl- and butyrylcholinesterase in human acoustic neuromas. <i>Neuroscience Letters</i> , 1999, 274, 56-60.	1.0	10
78	Acetylcholinesterase Is Increased in the Brains of Transgenic Mice Expressing the C-terminal Fragment (CT100) of the β -Amyloid Protein Precursor of Alzheimer's Disease. <i>Journal of Neurochemistry</i> , 1998, 71, 723-731.	2.1	92
79	Expression and Glycosylation of Acetylcholinesterase in Alzheimer's Disease Brain. , 1998, , 175-179.		0
80	Glycosylation of acetylcholinesterase as diagnostic marker for Alzheimer's disease. <i>Lancet</i> , The, 1997, 350, 929.	6.3	38
81	The Amyloid β -Protein of Alzheimer's Disease Increases Acetylcholinesterase Expression by Increasing Intracellular Calcium in Embryonal Carcinoma P19 Cells. <i>Journal of Neurochemistry</i> , 1997, 69, 1177-1184.	2.1	112
82	Molecular forms of acetyl- and butyrylcholinesterase in human glioma. <i>Neuroscience Letters</i> , 1996, 206, 173-176.	1.0	20
83	Biochemical properties of acetyl- and butyrylcholinesterase in human meningioma. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 1996, 1317, 210-218.	1.8	22
84	Monomers and dimers of acetylcholinesterase in human meningioma are anchored to the membrane by glycosylphosphatidylinositol. <i>Neuroscience Letters</i> , 1995, 195, 101-104.	1.0	16
85	Amphiphilic and hydrophilic forms of acetyl- and butyrylcholinesterase in human brain. <i>Journal of Neuroscience Research</i> , 1993, 35, 678-689.	1.3	45
86	Ricinus communis agglutinin I reacting and non-reacting butyrylcholinesterase in human cerebrospinal fluid. <i>Neuroscience Letters</i> , 1992, 145, 59-62.	1.0	20